Janux Therapeutics Inc
NASDAQ:JANX

Watchlist Manager
Janux Therapeutics Inc Logo
Janux Therapeutics Inc
NASDAQ:JANX
Watchlist
Price: 15.36 USD -1.41% Market Closed
Market Cap: 923.9m USD

EV/EBITDA
Enterprise Value to EBITDA

0.5
Current
-5.1
Median
6.7
Industry
Higher than median
Lower than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
0.5
=
Enterprise Value
-65.5m USD
/
EBITDA
-142.2m USD
All Countries
Close
EBITDA Growth EV/EBITDA to Growth
US
Janux Therapeutics Inc
NASDAQ:JANX
Average EV/EBITDA: 35.8
0.5
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -195 041.5 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.3
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
17.8
11%
1.6
US
Gilead Sciences Inc
NASDAQ:GILD
12.7
7%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.5
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -579.2 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.1
11%
1.5
AU
CSL Ltd
ASX:CSL
12.9
8%
1.6
NL
argenx SE
XBRU:ARGX
61.9
807%
0.1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
161.8
N/A N/A

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
0.4
2-Years Forward
EV/EBITDA
0.3
3-Years Forward
EV/EBITDA
0.2